IIL says Delhi-seized Abhayrab rabies vaccine vials are counterfeit
After CDSCO flagged misbranded and substandard Abhayrab vials seized from an unlicensed Delhi residence, Indian Immunologicals said the products were counterfeit and not made at its Human Biologicals Institute unit. The company has submitted manufacturing and distribution records and sought an investigation.
What happened
Indian Immunologicals Ltd (IIL) · CDSCO flagged misbranded, substandard Abhayrab rabies-vaccine vials seized from an unlicensed Delhi residence. IIL said the
Key facts
- Batch KE25012
- 17 differences
- 83,370 vials
- 54 rabies deaths in 2024
- 22 April 2026
- November 2025
- 14 August 2026
- September 4, 2026
Why this matters
The incident highlights strategic value in anti-counterfeit packaging, end-to-end serialization, and validated distribution partnerships across India’s vaccine supply chain.
What to watch
- CDSCO publication of batch numbers, test findings, recall instructions or broader state-level alerts.
- Police or drug-control disclosures identifying suppliers, distributors, clinics, e-commerce sellers or repeat counterfeit incidents.
- Reports of adverse events, failed vaccination outcomes or patient exposure linked to suspected vials.
- IIL announcements on QR/serialization verification, packaging changes, distributor restrictions or legal action.
- Evidence of hospital/pharmacy substitution toward rival rabies-vaccine brands or localized supply disruptions.
- Issue batch-level authenticity guidance for pharmacies, hospitals and consumers, including a verified reporting channel.
- Reconcile distributor-to-retailer movement records and quarantine any stock with unverifiable invoices, storage history or serial/batch details.
- Coordinate with CDSCO and state regulators on authenticated batch lists, testing results and public clarification separating genuine from counterfeit stock.
- Increase field audits of high-risk wholesalers, unlicensed sellers and digital/grey-market listings.
- Prepare continuity plans for rabies post-exposure prophylaxis demand if providers temporarily shift to alternative brands.